development in humans. Considering DISC1 is one of the main risk loci for psychiatric disorders and white matter integrity is highly heritable, the present data provide a plausible mechanistic link between enhanced genetic risk through inheritance of DISC1 genotypes and the development of psychiatric disorders.
Effect of CRMP3 expression on dystrophic dendrites of hippocampal neurons
We have previously shown that deleting CRMP3 gene altered prepulse inhibition of the acoustic startle response, 1 impaired long-term potentiation and induced dendritic dystrophy in hippocampus. 2 In cultured hippocampal neurons, CRMP3 expression resulted in numerous long-branched dendrites, which were inhibited by its dominant-negative isoform. 3 Because the levels of CRMP3 expression in hippocampal neurons correlated with dendrite morphogenesis, it is conceivable that CRMP3 may be a potential therapeutic target in neuronal dystrophy affecting hippocampal dendrites. In this study, we report that CRMP3 overexpression prevents dystrophy of dendrites occurring in a neurotoxic context. Figure 1 Results of tract-based spatial statistics comparing rs821616 A carriers to TT homozygotes. Voxels in which fractional anisotropy (FA) was significantly reduced in A carriers compared with TT homozygotes are shown in red-yellow. There were no voxels in which FA was increased in A carriers. For better visibility the tract-based spatial statistics skeleton has been thickened using the 'tbss_fill' command in FSL. The images are in radiological convention.
Dendritic pathology, including reduction of dendrite length/complexity, fragmentation and alteration of spine density/shape, are a prevalent theme during abnormal development and aging. Dendritic dystrophy is also implicated in diverse neuropsychiatric disorders such as schizophrenia, depression, Alzheimer's and prion diseases. Surprisingly, therapeutic strategies targeting dendritic dystrophy are almost non-existent. Although studies have demonstrated the influence of extracellular signals, such as neurotrophins, on dendrite morphology, the idea that endogenous molecules may be produced specifically to subserve the neuroprotective functions of hippocampal neurons is less well developed. These observations prompted us to investigate whether CRMP3 could reduce dendritic alterations that occur in a well-known prion peptide-induced neurotoxicity model. Prion peptide PrP 106-126 was identified as having a direct neurotoxic effect on primary neuronal cultures and the ability to mimic most characteristics of the scrapie prion (PrP Sc ), including a partial resistance to proteolysis and a strong tendency to aggregate in b-sheet structures. 4, 5 We treated cultured hippocampal neurons with PrP 106-126 or with scramble control peptide (CP) and quantitatively analyzed their dendrite morphology after MAP2 staining. In CP-treated cultures ( Figure 1a , panel 1), no difference in the dendrite length per neuron (479 ± 38 m) was observed compared with untreated cultures (506 ± 28 mm).
Incubation with PrP
106-126 induced a dramatic reduction in dendrite length (180 ± 17 mm) by 65 ± 5% over untreated/CP-treated controls (P < 0.01; Figure 1a . (957±71 mm) and PrP 106-126 (896±93 mm) treatment (Figure 1b, panels 3 and 4, a, panel 3, red columns) . These results show that PrP 106-126 induced dystrophic changes in dendrites, and this effect was prevented by an overexpression of CRMP3. Interestingly, it has been shown that in human subjects, while the extensive neuronal loss with spongiform degeneration of prion pathology affects mostly the basal ganglia, and the cerebral and cerebellar cortex, 6 ,7 the hippocampal formation-where CRMP3 is highly expressed-is protected until the final stage of disease. 8 It is conceivable that the high levels of CRMP3 expression in hippocampus compared with other brain areas, 2 especially cortex and basal ganglia, may explain the relative protection of this structure from the disease. Emerging from our data then is the potential use of an endogenous intracellular protein, CRMP3, as a novel therapeutic strategy to reduce or limit hippocampal dendritic dystrophy occurring during abnormal brain development or neurodegeneration.
How does CRMP3 preserve individual dendritic structure? Calcium signals triggered by various effectors control the growth and branching of dendrites, and release of calcium from intracellular stores maintains dendritic branch stability. 9 In contrast, after prolonged exposure, PrP 106-126 and scrapie homogenate induced neurite alterations and contortions via a reduction in Ca 2 þ entry and dysfunction of voltage-gated calcium channels, including CaV2.2. 10, 11 Relevant to these findings, using whole-cell voltage clamp electrophysiology, we found for the first time that transfection of CRMP3-EGFP enhanced Ca 2 þ current density via neuronal N-(CaV2.2) and P/Qtype (CaV2.1) voltage-gated calcium channels in hippocampal neurons (Figure 1c ). On average, the peak current density increased by B2.8-fold, from 10.4 ± 2.2 (n = 9) in control neurons to 29.2 ± 2.8 (n = 10) pA/pF in CRMP3-expressing neurons (holding potential of 5 mV, P < 0.05, ANOVA). Collectively, these observations suggest that CRMP3 activity on calcium flux may mediate its effects on dendrite formation. They provide a new foundation for further studies on the role of CRMP3 in Ca 2 þ trafficking and signaling, and to determine whether its effect on Ca CYP2D6 ultrarapid metabolizers (UMs) are subjects carrying more than two active alleles, and have a much higher hydroxylation capacity. Recently, a higher frequency of CYP2D6 active genes was found among patients with eating disorders (EDs) vs healthy controls. 1 Moreover, a higher frequency of UMs was found among individuals who committed suicide vs those who died from natural causes. 2 Therefore, the present study analyzed the relationship between CYP2D6 genetic polymorphism and lifetime suicidal behavior in ED patients.
Risk of suicide was retrospectively analyzed in 203 women with EDs (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) from a population previously genotyped. 1 As a part of the Diagnostic Interview Schedule, participants were asked 'Have you ever attempted suicide?'. The time frame for these questions was lifetime. A suicide attempt was defined as a self-destructive act with some degree of intent to end one's life. Thus, to be considered an attempt, the
